What Labs Should You Get Before Starting Longevity Treatment?

Short answer: For testosterone, Endocrine Society guidance requires baseline hematocrit, rechecks at 3–6 months and annually, and a structured response if hematocrit rises above 54%. Broader longevity panels (glucose, lipids, hs-CRP) are useful but less formally guideline-backed than TRT monitoring.

Getting the right baseline labs before starting a longevity program isn't just a formality — for some treatments, it's the difference between a monitored, evidence-based approach and flying blind. The good news: for the most common longevity therapies, real clinical guidelines already exist telling you exactly what to check and when. Here's what a genuinely well-run program should be doing.

If Testosterone Is Part of Your Program: A Real, Established Protocol Exists

This is the clearest, most evidence-backed monitoring protocol in the entire longevity space. The Endocrine Society's clinical practice guideline is explicit: measure baseline hematocrit before starting testosterone therapy, since testosterone increases red blood cell production and can raise hematocrit to unsafe levels.^[1]

This isn't a minor precaution. Testosterone-treated men in controlled studies were nearly four times more likely than placebo-treated men to develop a hematocrit above 50%, with risk increasing further with age.^[2] The guideline specifically advises against starting testosterone therapy at all in men whose baseline hematocrit already exceeds the upper limit of normal (48% generally, 50% at high altitude) without first discussing the added risk of erythrocytosis (excess red blood cells).^[1]

The monitoring schedule is clearly defined:

• Baseline: hematocrit check before starting
• 3–6 months in: hematocrit recheck, plus serum testosterone level
• Annually thereafter: ongoing hematocrit monitoring for the duration of therapy
• First year: prostate cancer risk evaluation

Metabolic and Cardiovascular Baseline Markers

Beyond hormone-specific monitoring, a peer-reviewed review of blood biomarkers linked to healthy aging identifies several markers with established associations to mortality risk and exceptional longevity in observational research: fasting glucose, total cholesterol, LDL cholesterol, high-sensitivity C-reactive protein (hs-CRP), and uric acid.^[3]

The hs-CRP marker specifically has a well-documented inflammation signal: cohort data shows individuals with hs-CRP levels above 3.0 mg/L had significantly higher all-cause mortality risk compared to those below 1.0 mg/L^[3] — making it a genuinely useful baseline and follow-up inflammation marker.

One interesting, slightly counterintuitive finding from this research: centenarians and long-lived individuals tend to maintain fasting blood glucose specifically within the 80–110 mg/dL range, and total cholesterol between 200–240 mg/dL after age 65^[3]— reference points that longevity-focused programs sometimes interpret differently from standard disease-screening cutoffs, since the population being studied (exceptionally long-lived people) isn't the same as the general disease-risk population most standard lab ranges are built around.

The Frontier: Epigenetic Aging Tests

Beyond conventional bloodwork, aging-biology researchers have developed epigenetic biomarkers like DunedinPACE — a DNA-methylation-based blood test designed to estimate your current pace of biological aging, rather than just measuring a single disease-risk marker.^[4]This is genuinely interesting science, but it's worth knowing where it currently sits: this class of test remains a research-stage tool, not a standardized clinical requirement the way hematocrit monitoring for testosterone is.

The Honest Distinction Worth Understanding

Here's the useful mental model: established, guideline-backed monitoring protocols currently exist primarily for specific hormone therapies like testosterone, backed by professional bodies like the Endocrine Society. Broader "longevity panel" biomarkers — things like ApoB, ferritin, and homocysteine — are supported mainly by observational cohort associations rather than randomized intervention trials.

That doesn't make the broader panel markers useless — the hs-CRP and glucose findings above are genuinely well-supported. It just means it's worth distinguishing between labs required by formal clinical practice guidelines (like hematocrit for testosterone) and labs offered as general wellness/optimization tracking, which are valuable but operate with a different, less formalized level of backing.

Comparing providers? SeeLongevity provider comparison by treatmenton RENVA's Longevity hub.

The Bottom Line

If your longevity program includes testosterone therapy, there's a clear, well-established answer for what labs you need and when — baseline hematocrit, rechecks at 3-6 months and annually, and a specific protocol if levels rise too high. For broader metabolic and inflammatory markers, fasting glucose, cholesterol, and hs-CRP all have real evidence behind them as useful baseline and tracking tools. A good longevity provider should be able to tell you clearly which category each lab they're offering falls into — and if you're on testosterone specifically, hematocrit monitoring isn't optional wellness tracking, it's an established safety protocol.

Frequently Asked Questions